Markets

Court Rules in Favor of Acadia Pharmaceuticals in Patent Litigation\n\nThe U.S. District Court for the District of Delaware has issued a Claim Construction Order in favor of Acadia Pharmaceuticals Inc. (Nasdaq:ACAD) regarding its ‘721 formulation patent for NUPLAZID® (pimavanserin), the company’s drug for the treatment of Parkinson’s Disease Psychosis. This is the second ruling issued today by the Court pertaining to Acadia’s patents covering NUPLAZID.\n\nIn the Order, the Court adopted Acadia’s interpretation of key disputed terms of the patent, affirming the strength of the patent. As a result, a claims construction hearing scheduled for December 19, 2023, has been cancelled. The case remains scheduled for trial in December 2024.\n\nAcadia’s formulation patent is set to expire in 2038, with a method of use patent on the 10mg tablet of NUPLAZID running to 2037 and a NUPLAZID composition of matter patent running to 2030. These patents, along with the recent rulings in favor of Acadia, demonstrate the strength and longevity of the company’s patent estate.\n\nNUPLAZID® (pimavanserin) is a selective serotonin inverse agonist and antagonist that targets 5-HT2A receptors, believed to play a role in neuropsychiatric disorders. It was approved by the U.S. Food and Drug Administration in 2016 for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.\n\nAcadia Pharmaceuticals has been at the forefront of healthcare for 30 years, developing and commercializing therapies for various neurological disorders. The company is also currently working on potential treatments for schizophrenia, Prader-Willi syndrome, Alzheimer’s disease psychosis, and other neuropsychiatric symptoms.\n\nIn a statement, Acadia’s President and CEO Steve Davis expressed the company’s satisfaction with the Court’s ruling and its impact on the ongoing patent litigation. He also emphasized the importance of establishing claims construction in patent litigation.

” Court Rules in Favor of Acadia Pharmaceuticals in Patent Litigation\n\nThe U.S. District Court for the District of Delaware has issued a Claim Construction Order in favor of Acadia Pharmaceuticals Inc. (Nasdaq:ACAD) regarding its ‘721 formulation patent for NUPLAZID® (pimavanserin), the company’s drug for the treatment of Parkinson’s Disease Psychosis. This is the second ruling issued today by the Court pertaining to Acadia’s patents covering NUPLAZID.\n\nIn the Order, the Court adopted Acadia’s interpretation of key disputed terms of the patent, affirming the strength of the patent. As a result, a claims construction hearing scheduled for December 19, 2023, has been cancelled. The case remains scheduled for trial in December 2024.\n\nAcadia’s formulation patent is set to expire in 2038, with a method of use patent on the 10mg tablet of NUPLAZID running to 2037 and a NUPLAZID composition of matter patent running to 2030. These patents, along with the recent rulings in favor of Acadia, demonstrate the strength and longevity of the company’s patent estate.\n\nNUPLAZID® (pimavanserin) is a selective serotonin inverse agonist and antagonist that targets 5-HT2A receptors, believed to play a role in neuropsychiatric disorders. It was approved by the U.S. Food and Drug Administration in 2016 for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis.\n\nAcadia Pharmaceuticals has been at the forefront of healthcare for 30 years, developing and commercializing therapies for various neurological disorders. The company is also currently working on potential treatments for schizophrenia, Prader-Willi syndrome, Alzheimer’s disease psychosis, and other neuropsychiatric symptoms.\n\nIn a statement, Acadia’s President and CEO Steve Davis expressed the company’s satisfaction with the Court’s ruling and its impact on the ongoing patent litigation. He also emphasized the importance of establishing claims construction in patent litigation.”$ACAD2023-12-15T18:53:10.537Z

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button